Photodynamic therapy for the treatment of non-melanoma skin cancer

• US 20040110731A1
• Filed: 12/04/2002
• Published: 06/10/2004
• Est. Priority Date: 12/04/2002
• Status: Abandoned Application

• Current Assignee: QT Incorporated
• Original Assignee: QT Incorporated
• Inventors: Chan, Agnes H., Neyndorff, Herma C.
• Application Number:
  US10/310,668
• Publication Number:
  US 20040110731A1
• Time in Patent Office: Days
• US Class Current: 514/169
• CPC Class Codes: A61K 41/0071 PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines

Abstract

The present invention relates to a method of treating non-melanoma skin cancer comprising: (a) intravenously administering a porphyrin based photosensitizer to a subject with non-melanoma skin cancer; (b) irradiating one or more tumors and a circumferential peritumoral margin of at least 1 mm with a light at a wavelength absorbed by said photosensitzer; wherein the irradiating step delivers a light dose of 180 J/cm2. It has been found that the above treatment gives extremely good efficacy while having a surprisingly good cosmetic outcome.

Claims

1. A method of treating non-melanoma skin cancer comprising:

(a) intravenously administering benzoporphyrin derivative monoacid A ring to a subject with non-melanoma skin cancers;

(b) irradiating one or more tumors and a circumferential peritumoral margin of 1-8 mm with a light at a wavelength of 688 nm (±

10 nm);

wherein the irradiating step delivers a light dose of 180 J/cm² (±

36 J/cm²).

3. A method according to claim 1 wherein the circumferential peritumoral margin is 3-4 mm.

4. A method according to claim 1 wherein the non-melanoma skin cancer is multiple basal cell carcinoma.

5. A method according to claim 1 wherein the non-melanoma skin cancer is squamous cell carcinoma.

6. A method according to claim 1 wherein the benzoporphyrin derivative monoacid A ring is delivered in the form of an aqueous lipid complex.

7. A method according to claim 1 wherein of 12-18 mg of BPD-MA is administered per m² of body surface area.

8. A method according to claim 1 wherein the intravenous administration is by an infusion over a 10 minute period.

9. A method according to claim 1 wherein the light dose is provided by light emitting diodes.

10. A method according to claim 1 wherein the light dose is administered over a 15 minute period.

11. A method according to claim 1 wherein the light dose is administered at an irradiance of about 200 mW/cm2.

2. A method of treating non-melanoma skin cancer comprising:

(a) intravenously administering verteporfin to a subject non-melanoma skin cancers;

(b) irradiating one or more tumors and a circumferential peritumoral margin of 1-8 mm with a light at a wavelength of 688 nm (±

10 nm);

wherein the irradiating step delivers a light dose of 180 J/cm2 (±

36 J/cm2).

14. A method according to claim 2 wherein the circumferential peritumoral margin is 3-4 mm.

15. A method according to claim 2 wherein the non-melanoma skin cancer is multiple basal cell carcinoma.

16. A method according to claim 2 wherein the non-melanoma skin cancer is squamous cell carcinoma.

17. A method according to claim 2 wherein of 12-18 mg of BPD-MA is administered per m² of body surface area.

18. A method according to claim 2 wherein the intravenous administration is by an infusion over a 10 minute period.

19. A method according to claim 2 wherein the light dose is provided by light emitting diodes.

20. A method according to claim 2 wherein the light dose is administered over a 15 minute period.

21. A method according to claim 2 wherein the light dose is administered at an irradiance of about 200 mW/cm².

12. An article comprising:

(a) verteporfin, and

(b) instructions for the use of the verteporfin for treating non-melanoma skin cancer by intravenously administering the verteporfin to a subject with non-melanoma skin cancers, and, after at least 1 hour but not more the 3 hours from the start of infusion, irradiating one or more tumor and a circumferential peritumoral margin of 3-4 mm with a light dose of 180 J/cm2 (±

36 J/cm2) said light being of a wavelength of 688 nm (±

10 nm).

13. An article according to claim 12 wherein the instructions indicate that 14 mg of BPD-MA should be administered per m2 of body surface area.